US FDA Approves First Intermediate-Risk Indication For TAVR
The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.
The expanded indication for Edwards' Sapien XT and Sapien 3 arrives about when the company had predicted.